Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Expert Calls for Full Verification of CEA Guidelines and Analytical Frameworks
A leading Japanese health economist has urged the government to carry out a substantive verification of Japan’s cost-effectiveness assessment (CEA) system, arguing that what authorities have so far labeled as “verification” falls far short of a genuine review. In an…
To read the full story
Related Article
- CEA Review Group Discusses Evidence for Additional Usefulness
June 17, 2026
- CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
- Are Technical Discussions Enough for Japan’s CEA System?
May 25, 2026
- JPMA Exec Urges Broader Debate on Japan’s CEA System
May 22, 2026
- Japan to Launch CEA “Technical Discussions” under MHLW Research Group
May 14, 2026
- Uncertainty Clouds Start of 6-Month CEA “Technical Discussions”
April 7, 2026
- Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- Industry Opposes Deeper CEA Price Cuts for “Cost-Increase” Products
November 13, 2025
- Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
REGULATORY
- CEA Review Group Discusses Evidence for Additional Usefulness
June 17, 2026
- Japan Sets 6-Billion-Yen Donation Target for Drug Discovery Fund
June 17, 2026
- Panel Questions Timing of Tavneos Blue Letter Action
June 17, 2026
- Minister Signals Chuikyo Review of Innovation Incentives after Roadmap
June 17, 2026
- MHLW Issues Guidance on Proper Use of GLP-1 Drugs
June 17, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…